Stock comparison
AbbVie Inc. is 34.5x more valuable than Axsome Therapeutics, Inc. by market capitalization ($441.54 B vs $12.81 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
ABBV is larger
AbbVie Inc. is 34.5x more valuable than Axsome Therapeutics, Inc. by market capitalization ($441.54 B vs $12.81 B).
Market value leader
ABBV
AbbVie Inc. is 34.5x more valuable than Axsome Therapeutics, Inc. by market capitalization ($441.54 B vs $12.81 B).
Revenue leader
ABBV
AXSM: $638.50M vs ABBV: $61.16B.
Profit leader
ABBV
AXSM: -$183.17M vs ABBV: $4.23B.
Margin leader
ABBV
AXSM: -28.7% vs ABBV: 6.9% net margin.
| Metric | AXSM | ABBV |
|---|---|---|
| Market cap | $12.81 B | $441.54 B |
| US-listed rank | #812 | #25 |
| Revenue (latest FY) | $638.50M | $61.16B |
| Net income (latest FY) | -$183.17M | $4.23B |
| Net margin | -28.7% | 6.9% |
| P/E (trailing FY) | - | 104.5x |
| SEC filings | 634 | 1,008 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
AbbVie Inc. is 34.5x more valuable than Axsome Therapeutics, Inc. by market capitalization ($441.54 B vs $12.81 B).
In their latest fiscal years, Axsome Therapeutics, Inc. reported $638.50M in revenue while AbbVie Inc. reported $61.16B.
Full pages: Axsome Therapeutics, Inc. and AbbVie Inc., or browse the full rankings.